Carvykti genetically modified autologous T cells for infusion Images

Generic Name: ciltacabtagene autoleucel

This medication has been identified as Carvykti genetically modified autologous T cells for infusion. It is supplied by Janssen Biotech, Inc.

Carvykti is used in the treatment of Multiple Myeloma and belongs to the drug class miscellaneous antineoplastics. Carvykti genetically modified autologous T cells for infusion is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Carvykti

Generic Name

ciltacabtagene autoleucel

Strength

genetically modified autologous T cells for infusion

Availability

Prescription only

Drug Class

Miscellaneous antineoplastics

CSA Schedule

Not a controlled drug

Labeler / Supplier

Janssen Biotech, Inc.

National Drug Code (NDC)

57894-0111

Drug Uses Add to Drug List Print

Get help with Imprint Code FAQs.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer